vs
Side-by-side financial comparison of GEN Restaurant Group, Inc. (GENK) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $49.7M, roughly 1.9× GEN Restaurant Group, Inc.). Vericel Corp runs the higher net margin — 25.0% vs -3.8%, a 28.8% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -9.0%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-5.6M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -1.0%).
Gen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
GENK vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $49.7M | $92.9M |
| Net Profit | $-1.9M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | -24.5% | 24.1% |
| Net Margin | -3.8% | 25.0% |
| Revenue YoY | -9.0% | 23.3% |
| Net Profit YoY | -821.4% | 17.3% |
| EPS (diluted) | $-0.37 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $49.7M | $92.9M | ||
| Q3 25 | $50.4M | $67.5M | ||
| Q2 25 | $55.0M | $63.2M | ||
| Q1 25 | $57.3M | $52.6M | ||
| Q4 24 | $54.7M | $75.4M | ||
| Q3 24 | $49.1M | $57.9M | ||
| Q2 24 | $53.9M | $52.7M | ||
| Q1 24 | $50.8M | $51.3M |
| Q4 25 | $-1.9M | $23.2M | ||
| Q3 25 | $-566.0K | $5.1M | ||
| Q2 25 | $-261.0K | $-553.0K | ||
| Q1 25 | $-301.0K | $-11.2M | ||
| Q4 24 | $-206.0K | $19.8M | ||
| Q3 24 | $25.0K | $-901.0K | ||
| Q2 24 | $277.0K | $-4.7M | ||
| Q1 24 | $496.0K | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | -24.5% | 24.1% | ||
| Q3 25 | -7.4% | 5.1% | ||
| Q2 25 | -3.4% | -3.2% | ||
| Q1 25 | -3.8% | -24.3% | ||
| Q4 24 | -2.4% | 24.5% | ||
| Q3 24 | 0.2% | -4.3% | ||
| Q2 24 | 3.0% | -11.5% | ||
| Q1 24 | 0.2% | -10.7% |
| Q4 25 | -3.8% | 25.0% | ||
| Q3 25 | -1.1% | 7.5% | ||
| Q2 25 | -0.5% | -0.9% | ||
| Q1 25 | -0.5% | -21.4% | ||
| Q4 24 | -0.4% | 26.3% | ||
| Q3 24 | 0.1% | -1.6% | ||
| Q2 24 | 0.5% | -8.9% | ||
| Q1 24 | 1.0% | -7.5% |
| Q4 25 | $-0.37 | $0.46 | ||
| Q3 25 | $-0.11 | $0.10 | ||
| Q2 25 | $-0.05 | $-0.01 | ||
| Q1 25 | $-0.06 | $-0.23 | ||
| Q4 24 | $-0.05 | $0.40 | ||
| Q3 24 | $0.01 | $-0.02 | ||
| Q2 24 | $0.06 | $-0.10 | ||
| Q1 24 | $0.11 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8M | $137.5M |
| Total DebtLower is stronger | $13.6M | — |
| Stockholders' EquityBook value | $26.5M | $354.6M |
| Total Assets | $259.9M | $488.0M |
| Debt / EquityLower = less leverage | 0.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | $137.5M | ||
| Q3 25 | $4.8M | $135.4M | ||
| Q2 25 | $9.6M | $116.9M | ||
| Q1 25 | $15.4M | $112.9M | ||
| Q4 24 | $23.7M | $116.2M | ||
| Q3 24 | $22.1M | $101.7M | ||
| Q2 24 | $29.2M | $102.5M | ||
| Q1 24 | $28.1M | $110.6M |
| Q4 25 | $13.6M | — | ||
| Q3 25 | $10.8M | — | ||
| Q2 25 | $7.8M | — | ||
| Q1 25 | $6.5M | — | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $7.7M | — |
| Q4 25 | $26.5M | $354.6M | ||
| Q3 25 | $38.1M | $321.9M | ||
| Q2 25 | $41.0M | $306.8M | ||
| Q1 25 | $42.8M | $295.5M | ||
| Q4 24 | $44.1M | $292.0M | ||
| Q3 24 | $46.5M | $257.5M | ||
| Q2 24 | $45.9M | $243.0M | ||
| Q1 24 | $40.4M | $233.9M |
| Q4 25 | $259.9M | $488.0M | ||
| Q3 25 | $245.5M | $453.3M | ||
| Q2 25 | $246.3M | $435.6M | ||
| Q1 25 | $232.4M | $424.6M | ||
| Q4 24 | $240.4M | $432.7M | ||
| Q3 24 | $225.7M | $390.4M | ||
| Q2 24 | $218.8M | $376.8M | ||
| Q1 24 | $214.5M | $356.7M |
| Q4 25 | 0.51× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | 0.15× | — | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-426.0K | $15.0M |
| Free Cash FlowOCF − Capex | $-5.6M | $12.8M |
| FCF MarginFCF / Revenue | -11.3% | 13.8% |
| Capex IntensityCapex / Revenue | 10.5% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-24.3M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-426.0K | $15.0M | ||
| Q3 25 | $-1.6M | $22.1M | ||
| Q2 25 | $3.3M | $8.2M | ||
| Q1 25 | $2.2M | $6.6M | ||
| Q4 24 | $7.3M | $22.2M | ||
| Q3 24 | $1.4M | $10.2M | ||
| Q2 24 | $5.6M | $18.5M | ||
| Q1 24 | $3.5M | $7.2M |
| Q4 25 | $-5.6M | $12.8M | ||
| Q3 25 | $-7.7M | $19.5M | ||
| Q2 25 | $-6.3M | $81.0K | ||
| Q1 25 | $-4.7M | $-7.6M | ||
| Q4 24 | $165.0K | $8.5M | ||
| Q3 24 | $-6.8M | $-9.2M | ||
| Q2 24 | $1.2M | $1.8M | ||
| Q1 24 | $-586.0K | $-6.8M |
| Q4 25 | -11.3% | 13.8% | ||
| Q3 25 | -15.3% | 28.8% | ||
| Q2 25 | -11.5% | 0.1% | ||
| Q1 25 | -8.2% | -14.5% | ||
| Q4 24 | 0.3% | 11.2% | ||
| Q3 24 | -13.9% | -15.9% | ||
| Q2 24 | 2.3% | 3.4% | ||
| Q1 24 | -1.2% | -13.3% |
| Q4 25 | 10.5% | 2.4% | ||
| Q3 25 | 12.0% | 3.9% | ||
| Q2 25 | 17.5% | 12.9% | ||
| Q1 25 | 11.9% | 27.0% | ||
| Q4 24 | 13.1% | 18.3% | ||
| Q3 24 | 16.9% | 33.5% | ||
| Q2 24 | 8.0% | 31.8% | ||
| Q1 24 | 8.1% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 57.96× | — | ||
| Q2 24 | 20.06× | — | ||
| Q1 24 | 7.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GENK
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
